State Medical Insurance Bureau: The establishment of pharmaceutical prices and recruitment credit evaluation system guidance.

Guide: The compliance mechanism is really in place! In accordance !---- with the spirit of the "Opinionof the State Council of the CPC Central Committee on Deepening the Reform of the Medical Security System" and other documents, the Bureau has studied and drafted the Guidance on the Establishment of a Credit Evaluation System for Pharmaceutical Prices and Recruitment (Draft for Comments), which is now open to the public for comments.members of the public may submit their comments and suggestions to us by 31 July 2020 in writing or by e-mail.E-mail address: yysmlc@nhsa.gov.cn address: 2-9, 2-9 North Street, Yuetan, Xicheng District, Beijing, Department of Pharmaceutical Price shipping and tender procurement, zip code: 100830 State Medical Security Administration July 24, 2020 on the establishment of pharmaceutical prices and recruitment The guidance of the credit evaluation system (draft for comments) the medical security bureaus of the provinces, autonomous regions, municipalities directly under the central government and xinjiang Production and Construction Corps: the acceptance of rebates, monopoly control and sale in the field of medicine resulted in inflated prices of medicines and medical supplies, excessive growth of medical expenses, large loss of medical insurance funds, seriously endangering the safety of medical insurance funds, infringing on the interests of the masses, and increasing the burden of medical expenses for the masses.in order to implement the Opinions of the State Council of the CPC Central Committee on Deepening the Reform of the Medical Security System (Cpc (2020) No. 5), improve the market-led mechanism for the formation of pharmaceutical prices, and establish a system of evaluation of pharmaceutical prices and recruitment of credit, the following comments are put forward... The guiding ideology is based on the civil rights and obligation relationship of centralized procurement of medicines and medical supplies, relying on the bidding and procurement platform for pharmaceuticaland medical supplies, system integration and trustworthiness commitment, credit rating, graded disposal, credit repair and other mechanisms, the establishment of equal rights and responsibilities, coordination of linked pharmaceutical prices and credit evaluation system, to promote honesty and trustworthiness of all parties, and jointly create a fair and standardized, clean and stable circulation order and security of the security of the people2. Establish a list of credit evaluation catalogues to establish a list of pharmaceutical prices and breach of trust, and the list of breach of trust includes, but not limited to, rebates or other improper benefits (hereinafter referred to as "pharmaceutical commercial bribery" in the purchase and sale of medicines), abuse of market dominance, tax-related violations, improper price violations, malicious violations of contract agreements, and disruption of centralized procurement order.since the date of issuance of this Opinion, pharmaceutical enterprises (including pharmaceutical production license holders, pharmaceutical and medical supplies production enterprises, distribution enterprises with entrusted agency relations with production enterprises, as well as distribution enterprises, the same below) in the pricing, bidding, performance, marketing and other processes, through the list of list of breach of trust to obtain improper benefits, including the scope of pharmaceutical prices and credit recruitment.. The voluntary commitment of pharmaceutical enterprises to participate in or entrust pharmaceutical enterprises to participate in the centralized procurement of pharmaceutical and medical supplies, platform network, as well as medical insurance fixed-point medical institutions (hereinafter referred to as "medical institutions") for the record procurement, should be independent legal entities to the pharmaceutical and medical supplies centralized procurement institutions (hereinafter referred to as "centralized procurement" The agency shall submit a written commitment, including the establishment of a compliance review system, the non-failure of credit listed in the catalogue, and the corresponding liability for the breach of trust committed by its employed personnel or the distribution enterprise with a entrusted agent relationship for its own medicineors or medical supplies;. Fourth, the establishment of the reporting channels of the loss of trust information to adopt the combination of enterprise reports and platform records, timely, comprehensive, complete and standardized collection of information on the behavior of pharmaceutical enterprises, the establishment of pharmaceutical enterprises price recruitment information base.pharmaceutical enterprises take the initiative to timely report the information of the loss of trust to the centralized purchasing organization where the breach of trust occurred.under the framework of cooperation established by the State Medical Security Administration and relevant departments, centralized procurement agencies regularly comb together the relevant departments open judgment instruments, administrative penalty decision instruments, etc., collect and verify the information of the medical enterprises for breach of trust and record it.centralized procurement agencies in the day-to-day operation through monitoring, correspondence, interviews, acceptance of reports and other means, to grasp the pharmaceutical enterprise pricing, bidding, performance and other aspects of the breach of trust information and record.V. To carry out the credit rating of pharmaceutical enterprises in accordance with the requirements of "reliable sources, clear conditions, strict procedures, strict operation" to implement the credit rating, according to the nature of the breach of trust, circumstances, timeliness, and the scope of influence and other factors, the pharmaceutical enterprises in the local tender procurement market to assess the breach of trust as general, medium, serious, particularly serious four grades, dynamic updates on a quarterly basis.the facts on which the credit rating is based on any breach of trust involving illegal and illegal acts shall be governed by the court's decision or the administrative punishment decision of the law enforcement department.encourage local governments to explore quantitative credit rating methods to improve the standardization of credit rating.6. The centralized procurement institutions for the classification of breach of trust shall, in accordance with the credit rating of pharmaceutical enterprises, respectively, adopt written reminders and warnings, prompt the purchaser with risk information by relying on the centralized procurement platform, suspend the bidding network of relevant drugs or medical supplies, suspend the supply and distribution of the winning drugs or medical supplies, and disclose the breach of trust to the public, and other disposal measures, and implement the liability of the pharmaceutical enterprise sist in breach of contract.the supply structure of drugs or medical supplies in case of a single, tight supply and demand situation, when taking graded disposal measures, should take into account accessibility. 7. Encourage pharmaceutical enterprises to repair credit to establish a mechanism for automatic credit repair and active repair of credit of pharmaceutical enterprises. If the breach of trust has been revoked for more than a certain period of time since its confirmation or if the relevant judicial judgment or administrative penalty decision is revoked according to law, the record shall be retained but no longer included in the credit rating range. to inform pharmaceutical enterprises before the effective disposition measures, and give certain complaints and rectification periods, as the case may be, allow enterprises to take practical measures to take practical measures to repair credit, including terminating related breach of trust, submitting compliance rectification reports and accepting compliance inspection, publicly issuing apology statements to eliminate adverse effects, removing the false space in the price of drugs or medical supplies involved, returning unreasonable public donations, etc. 8. The correct use of pharmaceutical prices and credit evaluation to establish a credit evaluation system for pharmaceutical prices and recruitment is an important measure to purify the order of the pharmaceutical market, optimize the environment for pharmaceutical business, and promote the high-quality development of the pharmaceutical industry. centralized purchasing institutions in various places to implement the evaluation of pharmaceutical prices and recruitment credit, should accept the guidance and supervision of the medical security department, adhere to laws and regulations as the criterion, market mechanism-oriented, civil rights and obligations as the fundamental, to ensure that pharmaceutical enterprises enjoy the right of independent pricing, independent management in accordance with the law; 9. Jointly promote the construction of credit evaluation system, centralized procurement agencies should establish and implement a provincial-based system of pharmaceutical price sourcing and credit evaluation by the end of 2020, adhere to the principle of sharing common management, promote the active participation of pharmaceutical enterprises and medical institutions, guide pharmaceutical enterprises to consciously fulfill their obligations to comply with price rules and operate in good faith, and guide medical institutions to choose better credit rating as supply or distribution units under the same conditions. centralized purchasing agencies should further promote standardized construction, improve bidding and procurement services, make full use of information-based means for pharmaceutical enterprises to submit commitments, record information, repair credit and other convenient and efficient services and support. .